← Back to patent-cliff list
F-18 Florastamin
Tier C — Watch / tradeF-18 Florastamin
FutureChem Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PSMA
Indications (approved)：Prostate cancer
Regional status
US
Discontinued
2021-02-01
EU
-
China
Phase III
2023-10-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of F-18 Florastamin?
Approved indications include: Prostate cancer.
When does the F-18 Florastamin patent expire?
No public expiry year is available for F-18 Florastamin yet; this page updates once verified.
How do I get a quote for F-18 Florastamin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02